Literature DB >> 9215658

Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1.

M Bulterys1, S Landesman, D N Burns, A Rubinstein, J J Goedert.   

Abstract

We evaluated maternal sexual behavior and injection drug use practices as possible risk factors for vertical transmission of human immunodeficiency virus type 1 (HIV-1). Data were analyzed from the Mothers and Infants Cohort Study, a prospective study in Brooklyn and the Bronx, New York. A total of 207 mother-infant sets were enrolled between 1986 and 1991 and followed for up to 4 years after the enrollment visit during pregnancy. HIV-1 transmission occurred in 49 of 201 mother-infant sets, yielding an overall transmission rate of 24.4% (95% confidence interval (CI) = 18.7% to 31.0%). Increased frequency of vaginal intercourse after the first trimester of pregnancy was positively associated with vertical transmission of HIV-1 (trend p = 0.03). A lifetime history of injection drug use was not associated with vertical transmission. However, a history of combined cocaine and heroin injection after the first trimester of pregnancy was associated with vertical HIV-1 transmission, particularly among women with CD4+ lymphocyte levels of 20% or higher (risk ratio = 4.0; 95% CI = 2.0 to 8.1). Cocaine and heroin injection drug use after the first trimester accounted for most of the relation between preterm birth and vertical HIV-1 transmission in this cohort. Maternal coinfection with hepatitis C virus or human T-cell lymphotropic virus types I and II could not explain these observations, because coinfection with these viruses had no detectable effect on HIV-1 transmission. These results suggest that maternal sexual behavior and injection drug use practices during the second and third trimester of pregnancy may modify the risk of vertical HIV-1 transmission.

Entities:  

Mesh:

Year:  1997        PMID: 9215658     DOI: 10.1097/00042560-199705010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  8 in total

1.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 2.  Molecular mechanisms of HIV-1 mother-to-child transmission and infection in neonatal target cells.

Authors:  Nafees Ahmad
Journal:  Life Sci       Date:  2010-10-01       Impact factor: 5.037

Review 3.  Associations between use of crack cocaine and HIV-1 disease progression: research findings and implications for mother-to-infant transmission.

Authors:  Judith A Cook
Journal:  Life Sci       Date:  2011-01-08       Impact factor: 5.037

4.  Morphine enhances HIV infection of neonatal macrophages.

Authors:  Yuan Li; Jeffrey D Merrill; Kathy Mooney; Li Song; Xu Wang; Chang-Jiang Guo; Rashmin C Savani; David S Metzger; Steven D Douglas; Wen-Zhe Ho
Journal:  Pediatr Res       Date:  2003-05-07       Impact factor: 3.756

5.  Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition.

Authors:  Sascha R Ellington; Caroline C King; Athena P Kourtis
Journal:  Future Virol       Date:  2011-11-24       Impact factor: 1.831

Review 6.  Prevention of mother to child transmission of HIV.

Authors:  Anju Kapoor; Anil Kapoor; Shashi N Vani
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 5.319

7.  Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study.

Authors:  S Grignolo; R Agnello; D Gerbaldo; C Gotta; C Alicino; F Del Puente; L Taramasso; B Bruzzone; C Gustavino; S Trasino; A DE Maria; G Icardi; C Viscoli; A DI Biagio
Journal:  Epidemiol Infect       Date:  2017-03-22       Impact factor: 4.434

Review 8.  Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.

Authors:  Omayma Amin; Jenna Powers; Katherine M Bricker; Ann Chahroudi
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.